Jaw-Dropping Academic Study Shows Natural Immunity Superior to COVID Vaccine

Posted on 08/26/2021

The global debate of COVID mRNA vaccine mandates and passports has ignited social media, policymakers, and policies that impact just nearly every aspect of public life. A number of major studies by universities are confirming basic biology principles about the power of natural immunity. Researchers at Maccabi Healthcare and Tel Aviv University compared the outcomes of over 76,000 Israelis in three groups. Keep in mind, the study is only published as a preprint at this stage and has not been peer reviewed. There was no external funding for the project.

The groups in the study were:
1. the doubly vaccinated (with the Pfizer vaccine)
2. Previously COVID infected but unvaccinated
3. Previously COVID infected with only a single vaccine dose

Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections
Sivan Gazit, Roei Shlezinger, Galit Perez, Roni Lotan, Asaf Peretz, Amir Ben-Tov, Dani Cohen, Khitam Muhsen, Gabriel Chodick, Tal Patalon
Link to study: https://www.medrxiv.org/content/10.1101/2021.08.24.21262415v1

The Israeli researchers discovered that immunity acquired through infection from COVID-19 is superior to immunity from the Pfizer-BioNTech vaccine. The study also found that fully-vaccinated but uninfected people were significantly more likely to have a “breakthrough” COVID infection than people who had previously been infected and recovered from the disease.

“This study demonstrated that natural immunity confers longer lasting and stronger protection against infection, symptomatic disease and hospitalisation caused by the Delta variant,” the authors conclude.

Earlier Study
There was also a July 2021 study called “Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells”

The study essentially highlights that most recovered COVID-19 patients mount broad, durable immunity after infection.

LINK: https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00203-2

The abstract reads, “Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. Here, we evaluate 254 COVID-19 patients longitudinally up to 8 months and find durable broad-based immune responses. SARS-CoV-2 spike binding and neutralizing antibodies exhibit a bi-phasic decay with an extended half-life of >200 days suggesting the generation of longer-lived plasma cells. SARS-CoV-2 infection also boosts antibody titers to SARS-CoV-1 and common betacoronaviruses. In addition, spike-specific IgG+ memory B cells persist, which bodes well for a rapid antibody response upon virus re-exposure or vaccination. Virus-specific CD4+ and CD8+ T cells are polyfunctional and maintained with an estimated half-life of 200 days. Interestingly, CD4+ T cell responses equally target several SARS-CoV-2 proteins, whereas the CD8+ T cell responses preferentially target the nucleoprotein, highlighting the potential importance of including the nucleoprotein in future vaccines. Taken together, these results suggest that broad and effective immunity may persist long-term in recovered COVID-19 patients.”

    Get News, People, and Transactions, Delivered to Your Inbox